| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00192-008-0761-1 |
| P698 | PubMed publication ID | 19002644 |
| P50 | author | Anastasios Athanasopoulos | Q37842647 |
| P2093 | author name string | Petros Perimenis | |
| P2860 | cites work | Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991 | Q22306385 |
| Adrenergic drugs for urinary incontinence in adults | Q24248668 | ||
| Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 | ||
| How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study | Q28202479 | ||
| Phenylpropanolamine and the risk of hemorrhagic stroke | Q31704504 | ||
| Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study | Q31817352 | ||
| The pharmacological treatment of urinary incontinence. | Q33778812 | ||
| Oestrogens and lower urinary tract function | Q34046273 | ||
| Clinical options for imipramine in the management of urinary incontinence | Q34276630 | ||
| Tolterodine: an overview | Q34473206 | ||
| Oxybutynin and the overactive bladder | Q34473215 | ||
| Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). | Q34473221 | ||
| Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia | Q34473227 | ||
| Prevalence and burden of overactive bladder in the United States | Q34534593 | ||
| The emerging role of solifenacin in the treatment of overactive bladder | Q34551577 | ||
| A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder | Q34594344 | ||
| Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review | Q34950386 | ||
| Female stress and urge incontinence in family practice: insight into the lower urinary tract | Q35018765 | ||
| Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra | Q35027384 | ||
| Pharmacological agents used for the treatment of stress urinary incontinence in women | Q35574096 | ||
| Antimuscarinics for treatment of overactive bladder | Q35615145 | ||
| Management of overactive bladder | Q35671074 | ||
| Clinical and socioeconomic relevance of overactive bladder. | Q35687979 | ||
| Current management of stress urinary incontinence | Q35771615 | ||
| Role of serotonin and noradrenaline in stress urinary incontinence | Q35771624 | ||
| Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder | Q35925590 | ||
| The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis | Q36122988 | ||
| Persistence with antimuscarinic therapy in patients with overactive bladder | Q36201756 | ||
| Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction | Q36301577 | ||
| Pathophysiology of overactive bladder | Q36399000 | ||
| Overactive bladder: The importance of new guidance. | Q36596773 | ||
| Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review | Q36610097 | ||
| Lower urinary tract symptoms, incontinence and falls in elderly people: time for an intervention study | Q36722436 | ||
| Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine | Q36869316 | ||
| The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis | Q37206637 | ||
| Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study | Q37292054 | ||
| Prevalence and incidence of urinary incontinence in community-dwelling populations | Q37906640 | ||
| Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. | Q40450175 | ||
| The patient with an overactive bladder--symptoms and quality-of-life issues | Q41679666 | ||
| Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial | Q43310817 | ||
| Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. | Q43993185 | ||
| Duloxetine versus placebo in the treatment of stress urinary incontinence | Q44062087 | ||
| Costs associated with the management of overactive bladder and related comorbidities | Q44200515 | ||
| Intravesical oxybutynin: a local anesthetic effect on bladder C afferents | Q44398144 | ||
| Urinary incontinence in Belgium: a population-based epidemiological survey | Q44432929 | ||
| Duloxetine Versus Placebo for the Treatment of North American Women With Stress Urinary Incontinence | Q44591404 | ||
| Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women | Q44637304 | ||
| New developments in the management of stress urinary incontinence | Q44893707 | ||
| Duloxetine: an innovative approach for treating stress urinary incontinence | Q44893712 | ||
| Antidiuresis: a new concept in managing female daytime urinary incontinence | Q44895157 | ||
| Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial | Q45012360 | ||
| Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity | Q45153417 | ||
| The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study | Q45269477 | ||
| Costs of urinary incontinence and overactive bladder in the United States: a comparative study. | Q45969424 | ||
| A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence | Q46430854 | ||
| Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. | Q46557454 | ||
| A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | Q46577111 | ||
| Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis | Q46591360 | ||
| Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms | Q48769881 | ||
| Employees with overactive bladder: work loss burden. | Q50761314 | ||
| Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat | Q51597666 | ||
| Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. | Q53248115 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. | Q53342637 | ||
| Prevalence of urinary incontinence. | Q55407150 | ||
| Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder | Q61613672 | ||
| Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg | Q61613683 | ||
| Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care | Q61868316 | ||
| A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag | Q73270831 | ||
| The FDA, regulation, and the risk of stroke | Q73299390 | ||
| Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder | Q74783033 | ||
| Postmenopausal hormone therapy and risk of developing urinary incontinence | Q75379837 | ||
| Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity | Q77346960 | ||
| Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence | Q79424407 | ||
| Pathophysiology of overactive bladder and urge urinary incontinence | Q80298118 | ||
| P433 | issue | 4 | |
| P921 | main subject | urinary incontinence | Q281490 |
| P304 | page(s) | 475-482 | |
| P577 | publication date | 2008-11-12 | |
| P1476 | title | Pharmacotherapy of urinary incontinence | |
| P478 | volume | 20 |
| Q37775254 | Acquired urinary incontinence in the bitch: update and perspectives from human medicine. Part 2: The urethral component, pathophysiology and medical treatment |
| Q51408125 | Analysis of clinical interventional strategy for women with urinary incontinence complicated with diabetes mellitus. |
| Q43093365 | Guidelines for the medical treatment of non-neurological urinary incontinence in women |
Search more.